Cross-sectional Study for Identification and Description of Severe Asthma Patients
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This will be a non-drug interventional cross-sectional study, where the screening visit and
study visit can occur on the same day. Investigational product will not be administered.
Approximately 790 subjects with severe asthma will be screened to achieve a total of at least
750 evaluable study subjects. The study will not include a run-in or follow-up period. This
study will provide a more reliable description of the severe asthma patient landscape with
respect to the potential eligibility for treatment with mepolizumab, omalizumab, and
reslizumab. This study aims to estimate the potential overlap of patients eligible for
treatment with mepolizumab and those eligible for treatment with omalizumab and/or
reslizumab. Additionally, the current study will also ascertain and describe reslizumab
eligibility with respect to both mepolizumab and omalizumab, in the severe asthma patient
population.